Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Hope Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$2,377,194

487 payments

Through program year 2025, Hope Clinical Research is reported as receiving $2,377,194 in research payments, across 487 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $688,689 193
2024 Research $261,927 19
2023 Research $26,453 15
2022 Research $119,358 29
2021 Research $153,516 76
2020 Research $348,674 71
2019 Research $778,577 84

Breakdown

Who paid Research payments · program years 2019–2025
  1. Boehringer Ingelheim International GmbH $711,894 196 payments
  2. Pfizer Inc. $569,108 44 payments
  3. Allergan Inc. $329,120 32 payments
  4. Gilead Sciences, Inc. $264,555 122 payments
  5. Novartis Pharmaceuticals Corporation $145,243 6 payments
  6. Merck Sharp & Dohme Corporation $117,965 8 payments
  7. ACADIA Pharmaceuticals Inc $99,864 14 payments
  8. GlaxoSmithKline, LLC. $44,595 15 payments
  9. Biogen, Inc. $32,779 1 payment
  10. Boehringer Ingelheim Canada Ltd.Ltee $23,367 34 payments
Studies the money was for Research payments · program years 2019–2025
  1. A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $408,618 124 payments
  2. A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study of the Longterm Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $306,252 13 payments
  3. A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis $280,071 69 payments
  4. Phase 2A Hepatic Impairment $189,797 16 payments
  5. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $140,527 10 payments
  6. A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis $114,927 4 payments
  7. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $107,807 1 payment
  8. A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir ISL, Doravirine DOR, and Doravirine,Islatravir DOR,ISL, Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR,ISL. $65,398 3 payments
  9. Acp-044-005 $52,057 7 payments
  10. Acp-044-005 $47,807 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record